Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | ADCY8 | P40145 | 2/20 | 0.45 |
| ▸ | ADCY1 | Q08828 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31144953 | 1.00 | PARP1 (0.50) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL11353354 | 0.84 | PARP1 (0.51) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL31133384 | 0.84 | RXRA (0.51) | CA1CA2RXRARXRBRXRG | |
| SCHEMBL1189514 | 0.84 | RXRA (0.48) | RXRARXRBRXRGCES2ADCY8 | |
| SCHEMBL627645 | 0.84 | RXRA (0.51) | CA1CA2RXRARXRBRXRG | |
| SCHEMBL3549811 | 0.83 | RXRA (0.47) | RXRARXRBRXRGCES2ADCY8 | |
| SCHEMBL12098032 | 0.83 | RXRA (0.47) | RXRARXRBRXRGCES2ADCY8 | |
| SCHEMBL29482057 | 0.83 | CES2 (0.46) | CES2NOTUMGAAMAOB | |
| SCHEMBL628084 | 0.83 | RXRA (0.43) | RXRARXRBRXRGADCY8ADCY1 | |
| SCHEMBL1189091 | 0.83 | NOTUM (0.66) | CA1CA2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| WO-2024175804-A1 | NUCLEAR TRANSPORT MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-08-29 | — | — | WO | disclosed |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-8541432-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-09-24 | — | — | US | disclosed |
| US-8501756-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8492393-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-07-23 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| WO-2008107390-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| EP-1964548-A1 | Pharmaceutical compositions comprising a calcilytic agent | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1765814-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006003096-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2006-01-12 | — | — | WO | disclosed |
| WO-2002064558-A2 | OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYTOKINE INHIBITORS | SANKYO COMPANY, LIMITED (JP) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236097-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | PARP1 4824/4885PARP10 3938/4885CA1 1421/4885 |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | PARP1 4824/4885PARP10 3938/4885CA1 1421/4885 |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | CACNA1A, BMP4, TPX2 | PARP1 2516/4885PARP10 1405/4885CA1 1465/4885 |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | GLP1R, GIPR, GCGR | PARP1 2877/4885PARP10 4090/4885CA1 3749/4885 |
| US-20200102318-A1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SCN11A, SCN10A, CACNA1A | PARP1 4824/4885PARP10 3938/4885CA1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.